Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (1619)	4/3/2001 8:14:44 PM
From: Jibacoa	Respond to of 2344

Thanks Wilder, I appreciate your opinion, it seems to me your intentions are honest.<g> <<I did not post this to pick a fight or to try to handle technical questions.>> I usually don't pick fights, since I am a little too old for that.<g> I still think Biomira's THERATOPE has good possibilities and they seem to have enough money to complete the trial. As you said if the results come out good you could probably buy it 30 points higher and still make good money, but 30 points higher would be out of my "buying range".<g> RAGL Bernard

To: keokalani'nui who wrote (1619)	4/5/2001 10:31:25 PM
From: Jibacoa	Read Replies (1) \| Respond to of 2344

Well, it seems that the news about the "partner" are coming out soon as previously expected.<g> Biomira set to name vaccine co-marketer -- BusinessWeek NEW YORK, April 5 (Reuters) - Biotechnology company Biomira Inc. <BIOM.O><BRA.TO> will name a partner to co-market its Theratope vaccine for metastatic breast cancer in a few weeks, according to the Inside Wall Street column in BusinessWeek. The partner, one of two big European drug makers, will pay $10 million upfront and acquire an equity stake in Edmonton, Canada-based Biomira, the magazine reports in in its April 16 issue, citing an investment manager. Biomira has enrolled 903 patients for its Phase III clinical trial of the vaccine, the magazine reported. Biomira officials could not immediately be reached for comment. Shares of Biomira rose 5/16, or 5.5 percent, to $6 on the Nasdaq on Thursday,off a 52-week high of $12-7/8. 22:01 04-05-01 Good luck to all. Bernard P.S.:The news are also in Yahoo: biz.yahoo.com